Zymeworks Long Term Debt 2016-2022 | ZYME

Zymeworks long term debt from 2016 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Zymeworks Annual Long Term Debt
(Millions of US $)
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $4
2015 $
Zymeworks Quarterly Long Term Debt
(Millions of US $)
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31 $5
2016-12-31 $4
2016-09-30
2016-06-30
2016-03-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.404B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.991B 9.65
GSK (GSK) United Kingdom $72.663B 8.73
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.304B 18.93
Biohaven Pharmaceutical Holding (BHVN) United States $10.553B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.041B 0.00
Arcus Biosciences (RCUS) United States $1.868B 36.45
Myovant Sciences (MYOV) United Kingdom $1.698B 0.00
Emergent Biosolutions (EBS) United States $1.490B 8.64
Enzo Biochem (ENZ) United States $0.131B 0.00
Gelesis Holdings (GLS) United States $0.117B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00